Stanley Y. Shaw, MD, PhD

The Shaw laboratory seeks new ways to phenotype patients and understand disease biology, through a combination of patient-focused studies, functional genomics, chemical biology and nanotechnology.  The overall goal is to use novel phenotypes to study disease mechanisms, understand the function of disease alleles for genetically complex diseases, and devise new therapeutic approaches.

Dr. Shaw is Co-Founder and Co-Director of the Center for Assessment Technology and Continuous Health (CATCH), which seeks to develop quantitative phenotypes, digital health tools, and integrative analytics for biomedical discovery. For more information on CATCH, please visit

A major effort within the lab uses data mining approaches applied to Electronic Medical Records (EMR) to phenotype patients using data acquired in the course of their usual clinical care. For instance, an NIH-funded effort has generated a cohort of 65,000 diabetics within the Partners Healthcare EMR. EMR-based phenotypes are analyzed in concert with biospecimens obtained as discarded samples, which yield cells for genetic and epigenetic characterization.

Dr. Shaw also directs a high-throughput chemical biology facility within the Center for Systems Biology. We have successfully used targeted chemical screens to identify pathways that functionally interact with disease alleles, and suggest new therapies.

Contact Info:

Massachusetts General Hospital
Center for Systems Biology
Simches Research Building
185 Cambridge Street, 5.226
Boston, MA 02114


[javascript protected email address]
Center for Systems Biology